NMN and NR Sexual Function Impact: What the Clinical Evidence Actually Shows

Why NAD+ Biology Connects to Sexual Function

NAD+ is not a sex hormone. The connection to sexual function runs through three converging pathways: mitochondrial energy metabolism, vascular endothelial signaling, and sex-hormone biosynthesis. Each of those pathways depends on adequate cellular NAD+ concentrations, and those concentrations fall with age.

The Mitochondrial Energy Angle

Sexual arousal, erection, and orgasm all demand sudden, substantial ATP output from smooth muscle cells, pelvic-floor neurons, and genital vascular endothelium. Mitochondrial oxidative phosphorylation accounts for the majority of that ATP, and NAD+ is the rate-limiting electron carrier in that process. When NAD+ is depleted, Complex I of the electron transport chain slows, ATP yield drops, and tissues that need burst-energy capacity, including corpus cavernosum smooth muscle, become less responsive [1].

Preclinical data in aged mice show that restoring NAD+ with NMN reverses age-related declines in muscle mitochondrial function within four to six weeks [2]. Whether that recovery extends cleanly to human pelvic tissue has not been formally tested, but the mitochondrial biology is conserved across tissues.

Endothelial Nitric Oxide Synthase (eNOS) Dependence

Penile erection and clitoral engorgement both depend on nitric oxide (NO) released by endothelial cells lining the cavernous arteries. ENOS is an NAD+-consuming enzyme. When endothelial NAD+ falls, eNOS activity declines, NO bioavailability shrinks, and the vasodilatory signal that drives engorgement weakens [3].

This is the same pathway targeted by PDE5 inhibitors (sildenafil, tadalafil): they amplify the NO signal downstream. NMN and NR work upstream, at the point of NO synthesis itself. A 2021 study in aged mice demonstrated that NMN restored endothelial function and aortic NO production to levels comparable to younger controls [4]. Human trials specifically measuring penile or vaginal blood flow after NMN supplementation have not yet been published.

Sex-Hormone Biosynthesis Connections

Steroidogenesis, the biochemical chain that converts cholesterol to testosterone and estradiol, requires NAD+-dependent enzymes at multiple steps. SIRT1, a NAD+-dependent deacetylase, regulates StAR protein expression in Leydig cells; StAR transports cholesterol into mitochondria, the first committed step of androgen production [5]. Low NAD+ may therefore mute testicular testosterone output at the enzymatic level, independently of LH signaling.

In ovarian granulosa cells, SIRT1 and SIRT3 activation supports follicular development and reduces oxidative damage to oocytes. These are indirect fertility-relevant effects rather than direct libido signals, but they matter in clinical practice because testosterone and estradiol are the primary hormonal drivers of sexual desire in both sexes.

What the Human Trials Actually Measured

No phase II or phase III RCT has used sexual function as a primary endpoint for NMN or NR supplementation. What exists is a set of trials with metabolic primary endpoints and, in a few cases, quality-of-life secondary data.

The Yoshino 2021 Trial (Insulin Sensitivity in Postmenopausal Women)

Yoshino et al. Published the most-cited human NMN trial in Science in 2021 [6]. Researchers randomized 25 postmenopausal women with prediabetes or overweight to NMN 250 mg/day or placebo for 10 weeks. The primary finding: NMN increased skeletal muscle insulin sensitivity by approximately 25% compared to placebo (P<0.05), measured by hyperinsulinemic-euglycemic clamp. Muscle NAD+ metabolite content rose significantly.

The trial did not measure libido, sexual satisfaction, or arousal. Postmenopausal women in this cohort had a mean age of 60 years, a group in whom insulin resistance and declining NAD+ both correlate with reduced sexual function in observational data. The mechanistic plausibility is real; the direct evidence is absent.

Older-Adult Safety and Tolerability Trials

A 2022 randomized crossover study by Connell et al. (N=30, mean age 71) tested NR 1,000 mg/day for six weeks and found significant increases in whole-blood NAD+ metabolites with no serious adverse events [7]. Quality-of-life questionnaires were collected but not powered for subscale analysis. Energy and fatigue scores improved numerically, which is relevant background for sexual function (fatigue is among the top patient-reported barriers to sexual activity in older adults), but no subscale reached statistical significance.

NR and Cardiovascular Endothelial Function in Humans

A 2018 trial by Martens et al. In Hypertension (N=30 older healthy adults) showed that NR 1,000 mg/day for six weeks reduced aortic stiffness by 9% and systolic blood pressure by 3.9 mmHg compared to placebo [8]. Vascular stiffness and hypertension are independent risk factors for erectile dysfunction. This is not a sexual-function trial, but improved arterial compliance is a plausible mechanism through which NR could support erectile and arousal responses.

The Male Sexual Function Picture

Erectile Dysfunction and Vascular NAD+

Erectile dysfunction (ED) is predominantly a vascular disease in men over 40. The Massachusetts Male Aging Study found that 52% of men aged 40 to 70 had some degree of ED, with vascular insufficiency driving the majority of cases [9]. NAD+ depletion exacerbates endothelial dysfunction through at least two routes: reduced eNOS activity (covered above) and increased PARP-1 activation, which consumes NAD+ during oxidative-stress repair cycles and creates a futile loop that further depletes the NAD+ pool.

Preclinical data in diabetic mice, a validated vascular-ED model, show that NMN supplementation partially restored intracavernosal pressure responses and eNOS phosphorylation over eight weeks [10]. That is a meaningful proof-of-concept, not a clinical outcome.

Testosterone and Libido in Men

The SIRT1-StAR pathway described above remains largely a preclinical finding. No human trial has demonstrated a statistically significant increase in serum testosterone from NMN or NR supplementation at standard doses. Clinicians should not prescribe NMN as a testosterone-boosting agent on current evidence.

What is established: NAD+ repletion in metabolically compromised men may secondarily support the hormonal environment by improving insulin sensitivity (hyperinsulinemia suppresses SHBG and alters androgen metabolism) and reducing systemic inflammation (which suppresses LH pulsatility). These are indirect effects that could translate to modest improvements in free testosterone over months, not weeks.

The Female Sexual Function Picture

Menopause, NAD+ Decline, and Genital Tissue Changes

Estradiol withdrawal at menopause accelerates NAD+ depletion in vaginal epithelial cells and reduces mitochondrial density in genital smooth muscle. A 2020 review in Menopause noted that genitourinary syndrome of menopause (GSM) involves mitochondrial dysfunction as a contributing factor to vulvovaginal atrophy [11]. NMN and NR are not FDA-approved treatments for GSM, and vaginal estrogen remains the gold-standard intervention for the tissue changes themselves.

The Yoshino 2021 cohort was exclusively postmenopausal women, and the metabolic improvements seen (insulin sensitivity, skeletal-muscle NAD+ content) overlap mechanistically with the cellular environment of genital tissue health. Whether NMN directly improves vaginal lubrication, arousal, or the pain associated with GSM is unknown.

Female Libido and Mitochondrial Energy Demands

Female sexual response requires sustained pelvic blood flow, clitoral smooth-muscle relaxation, and vaginal transudation, all energy-intensive processes. The Female Sexual Function Index (FSFI) correlates inversely with metabolic syndrome markers in multiple cross-sectional studies. If NMN improves metabolic parameters, a secondary benefit to FSFI scores is biologically plausible. No trial has tested this directly.

Dosing Considerations for Sexual Health Applications

Clinicians and patients asking about NMN or NR for sexual-function support should understand that no dose has been validated for this indication. The doses studied in human trials range widely.

NMN Dosing

• 250 mg/day: The Yoshino 2021 dose; produced significant metabolic effects in 10 weeks.
• 500 mg/day: Used in the Irie et al. 2020 safety trial (N=10), which confirmed tolerability and dose-dependent NAD+ metabolite rises [12].
• 900 to 1,200 mg/day: Under investigation in ongoing trials; human safety data at these doses are limited as of early 2025.

Most commercial NMN supplements are dosed at 250 to 500 mg/day. Sublingual and liposomal formulations claim higher bioavailability than standard capsules, but no comparative pharmacokinetic trial in humans has confirmed a clinically meaningful difference in tissue NAD+ levels.

NR Dosing

NR at 300 to 1,000 mg/day has been the most studied range in humans. The Martens 2018 vascular trial used 1,000 mg/day. The Connell 2022 older-adult trial also used 1,000 mg/day. Both confirmed NAD+ metabolite elevation and tolerability. NR is typically taken once or twice daily with food.

Timing and Stacking Considerations

Some clinicians combine NMN or NR with pterostilbene or resveratrol on the rationale that SIRT1 activation requires both NAD+ substrate and a sirtuin activator. Evidence for this combination specifically in sexual function is absent. Combining NAD+ precursors with PDE5 inhibitors is mechanistically logical (upstream vs. Downstream NO pathway support) but has not been studied in a controlled trial. Patients using PDE5 inhibitors for ED should not discontinue them based on NMN supplementation alone.

Safety Profile Relevant to Sexual Health Contexts

General Tolerability

Across published human trials, NMN and NR are well tolerated at doses up to 1,000 mg/day for periods of six to twelve weeks. The most common adverse effects are mild and GI-related: nausea, bloating, and loose stools reported in roughly 10 to 15% of participants [7, 12]. No serious adverse events attributable to NMN or NR have been published in peer-reviewed literature as of 2025.

Hormone Interactions

No published trial has demonstrated that NMN or NR alters serum estradiol, LH, FSH, or prolactin in humans. Theoretical SIRT1-mediated effects on steroidogenic enzyme activity exist in preclinical models. Patients on hormone replacement therapy (HRT) or testosterone replacement therapy (TRT) can take NMN or NR concurrently based on current evidence, but monitoring baseline hormones before and after supplementation is appropriate clinical practice.

Contraindications and Cautions

NMN and NR have no established drug interactions in peer-reviewed pharmacokinetic literature. Caution is appropriate in patients with active cancer or a recent cancer history because NAD+ is a substrate for cancer-cell proliferation pathways, though no human trial has shown NMN or NR to accelerate cancer growth. Patients should discuss supplementation with their oncologist before starting.

How NMN and NR Fit Into a Broader Sexual Health Protocol

Sexual dysfunction in aging adults is multifactorial. NMN and NR address NAD+ depletion, which is one contributor among many. A complete clinical picture should include:

1. Hormone testing. Total and free testosterone, estradiol, SHBG, DHEA-S, prolactin, and thyroid function. Addressing a documented hormone deficiency with FDA-approved therapies (testosterone, estradiol, vaginal DHEA) will produce a larger, faster effect on sexual function than any NAD+ precursor.

2. Vascular risk assessment. ED in men under 60 predicts cardiovascular events with a 10-year hazard ratio of approximately 1.6 in the Olmsted County cohort [13]. Optimize blood pressure, LDL, and HbA1c before or alongside supplementation.

3. Sleep and cortisol. Chronic sleep deprivation suppresses testosterone by 10 to 15% in young men after one week of restricted sleep (5 hours/night) [14]. No supplement corrects this. Fix sleep architecture first.

4. PDE5 inhibitor access. Sildenafil and tadalafil remain the most evidence-backed interventions for vascular ED, with response rates of 70 to 80% in unselected ED populations. NMN is not a substitute.

NMN and NR are best positioned as adjunctive metabolic support in patients who already have a baseline sexual-health protocol in place, not as first-line or standalone treatments.

What Clinicians and Patients Should Expect

The honest clinical answer is that NMN and NR may improve sexual function indirectly, through better mitochondrial energy supply, improved endothelial function, and modestly improved insulin sensitivity, but the evidence for a direct, measurable sexual-function benefit in humans does not yet exist.

Patients who report improved energy, reduced fatigue, and better metabolic markers after six to twelve weeks of supplementation may notice secondary improvements in sexual interest and performance. Those effects are plausible and worth tracking clinically. Formal patient-reported outcome tools like the International Index of Erectile Function (IIEF) or the FSFI can quantify changes in a way that subjective reports cannot.

The field is moving. As of early 2025, multiple phase II trials with broader quality-of-life endpoints, including sexual function subscales, are recruiting or in analysis. The next 24 to 36 months should produce more direct data.

As the Endocrine Society's 2023 clinical practice guidance on aging and testosterone notes: "Testosterone therapy should be considered only when there is documented biochemical hypogonadism," a reminder that symptom overlap between NAD+ depletion and hormone deficiency is substantial, and measurement, not empirical supplementation, should guide the first intervention [15].